Cooperative Agreement U01DA064384
Award Date
7/15/25
Completion Date
3/31/28
Dollars Obligated
$2.8M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to Flik Therapeutics, Inc. to support the development of a novel FDA-regulated pharmacotherapy and multimodal nicotine cessation program. The goal is to create a more effective smoking cessation therapy compared to the current standard of care, which has low success rates. This Phase I proposal will fund the initial development of the...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, is funding a Phase II clinical trial to evaluate the use of the drug tirzepatide (Zepbound) in adults with co-occurring alcohol use disorder and overweight/obesity. The $211,247 award supports an 8-week double-blind study at the University of Southern California to assess the effects of tirzepatide on alcohol use, weight,...
This federal Project Grant award, identified as R21DA059769, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is funding a randomized, double-blind, crossover human laboratory study to assess the efficacy of D9-tetrahydrocannabivarin (D9-THCV), a naturally occurring cannabinoid, as a potential treatment for nicotine dependence and smoking cessation. The $196,875 award will support a study of 32 daily...
The National Institute on Drug Abuse (NIDA) awarded a $742,500 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 3-year pilot study. The grant will fund the adaptation and pilot testing of a peer recovery coach-delivered tobacco cessation intervention, called PEERTTS, for individuals with opioid use disorder (OUD) and tobacco use disorder (TUD). The project aims to evaluate the...
The National Institute on Drug Abuse (NIDA) awarded Duke University a Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate digital envirotyping methods for characterizing the everyday environments of people who smoke. The $763,766 award, which runs from July 2025 to March 2030, aims to (1) advance digital envirotyping and enviromarker development to identify environmental triggers of smoking relapse, and (2) increase understanding of...
This Project Grant award of $702,965 was provided by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the award is to conduct a pilot mechanistic study to evaluate the potential of the drug semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA), as a treatment for cocaine use disorder (CUD). The 4-year study, which will run from June 2025 to February 2029, will assess semaglutide's impact on key...
This Project Grant award of $3,257,011 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will fund a randomized controlled trial to evaluate the effectiveness of switching to electronic nicotine delivery systems (ENDS) compared to nicotine replacement therapy (NRT) for promoting smoking abstinence among individuals enrolled in substance use disorder (SUD) treatment programs in South Carolina. The study aims to: 1) assess...
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...
This Cooperative Agreement award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and validate a novel patient-reported outcome measure of substance-related consequences for use in substance use disorder (SUD) treatment trials. The $352,064 award, effective from August 1, 2025 to July 31, 2027, will be executed by the Mclean Hospital Corporation, a non-profit psychiatric teaching hospital affiliated with...